Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Enters into an agreement with a "leading biopharmaceutical company" to support the ongoing development of a biosimilar product. Says this revenue-generating collaboration follows an earlier technology partnership between the two companies, utilising Arecor's proprietary technology platform, Arestat, and formulation expertise.

Chief Executive Officer Sarah Howell says: "This collaboration demonstrates the strength of our know-how and expertise and the value that expertise can bring to our partners' research programmes. We're delighted to be working again with an existing partner, strengthening a key relationship and building on our track record of partnerships with leading biopharmaceutical and biotechnology companies."

Current stock price: 221.00 pence, down 3.9% on Wednesday

12-month change: down 32%

By Sophie Rose, Alliance News reporter

Comments and questions to

Copyright 2023 Alliance News Ltd. All Rights Reserved.